Table 1.
Clinical characteristics of the 98 HSCT recipients.
| Characteristic | N (%) |
|---|---|
| Age, median (range), years | 52.1 (19.6 – 73) |
| Gender | |
| Male | 60 (61%) |
| Female | 38 (39%) |
| Underlying disease | |
| Acute leukemia | 44 (45%) |
| Lymphoma/CLL | 22 (23%) |
| Myelodysplastic syndrome/MPD | 21 (21%) |
| Multiple myeloma | 9 (9%) |
| Nonmalignant hematologic disorders | 2 (2%) |
| Stem cell source | |
| Peripheral blood | 74 (76%) |
| Bone marrow | 3 (3%) |
| Cord blood | 21 (21%) |
| Graft type | |
| T-cell depleted | 49 (50%) |
| Conventional | 49 (50%) |
| Donor type | |
| Matched related donor | 26 (26%) |
| Matched unrelated donor | 32 (33%) |
| Mismatched unrelated donor | 40 (41%) |
| Type of conditioning | |
| Myeloablative (MA) | 50 (51%) |
| Reduced intensity (RIC) | 38 (39%) |
| Nonmyeloablative (NMA) | 10 (10%) |
| Conditioning regimen | |
| Total body irradiation containing | |
| High dose (>1300 Gy) | 17 (17%) |
| Low dose (≤400 Gy) | 57 (58%) |
| All chemotherapy | 24 (25%) |
| Acute GVHD | |
| Grade 0-1 | 64 (65%) |
| Grade 2-3 | 32 (33%) |
| Not evaluable | 2 (2%) |
| Keratinocyte growth factor (Palifermin) | |
| Yes | 30 (31%) |
| No | 68 (69%) |
| Ciprofloxacin within 14 days of stem cell infusion | |
| Yes | 35 (36%) |
| No | 63 (64%) |
| Recipient serum BKV IgG titers | |
| >1:640 | 98 (100%) |
| CMV serology | |
| R+/D+ | 28 (28%) |
| R+/D− | 33 (34%) |
| R−/D+ | 8 (8%) |
| R−/D− | 29 (30%) |
| CMV reactivation | 37 (38%) |
Abbreviations: HSCT, hematopoietic stem cell transplantation; GVHD, graft versus host disease; TBI, total body irradiation; CMV, cytomegalovirus; R+, recipient positive; R−, recipient negative; D+, donor positive; D−, donor negative